MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611108196 A) filed by Noida Institute Of Engineering And Technology Pharmacy Institute on September 09, 2026, for Triple Stimuli-Responsive Hyaluronic Acid–polyhistidine Nanogel For Synergistic Anti- Inflammatory Drug Delivery.
Inventors include Mr. Abhijit Debnath; and Ms. Shruti Varshney.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention discloses a triple stimuli-responsive hybrid nanogel drug delivery system comprising hyaluronic acid conjugated with polyhistidine through amide bonds and crosslinked via reducible disulfide bonds from cystamine, for targeted delivery of anti-inflammatory agents to inflamed tissues. The nanogel responds to three disease-associated stimuli: acidic pH through protonation of polyhistidine imidazole groups causing nanogel swelling, hyaluronidase through enzymatic degradation of the hyaluronic acid backbone, and elevated intracellular glutathione through reductive cleavage of disulfide crosslinks. The hyaluronic acid component provides CD44 receptor-mediated targeting to activated inflammatory cells. The optimised nanogel exhibits mean diameter of 185 nanometres, polydispersity index of 0.18, ibuprofen encapsulation efficiency of 58.7 percent, and cumulative release of 89.4 percent under combined triple stimuli versus 12.3 percent at physiological pH. In vitro studies demonstrate 74 percent reduction of TNF-alpha in lipopolysaccharide-stimulated macrophages, representing 2.1-fold enhancement over free ibuprofen.
Disclaimer: Curated by HT Syndication.
